1. Home
  2. Live Updates
  3. Krankenhaus nordwest

Live Breaking News & Updates on Krankenhaus nordwest

Stay informed with the latest breaking news from Krankenhaus nordwest on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Krankenhaus nordwest and stay connected to the pulse of your community

First Patient Dosed in Trial Evaluating Efti and the Anti-PD-L1 Therapy BAVENCIO® in Metastatic Urothelial Cancer

Media ReleaseSYDNEY, AUSTRALIA, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ('Immutep” or “the Company”), a clini...

United-states , Germany , Australia , Sydney , New-south-wales , Australian , German , Krankenhaus-nordwest , Chris-basta , Drug-administration , Immutep-limited , Us-national-cancer-institute

Imfinzi-Chemo Combo Shows Promise in Ongoing Gastric Cancer Trial

The addition of Imfinzi to a chemotherapy regimen called FLOT tended to boost pathologic complete response rates in patients with gastric or gastroesophageal junction cancer.

Germany , German , Krankenhaus-nordwest , Salah-eddin-al-batran , University-cancer-center , Institute-of-clinical-cancer-research , Clinical-cancer-research , Gastrointestinal-oncology , Krankenhaus-nordwest-university-cancer-center , News , Gastric-cancer ,

Duvalumab Plus Chemotherapy Elicits pCR Improvement in Resectable Gastric/GEJ Cancer

The addition of durvalumab to 5-fluorouracil, leucovorin, oxaliplatin, and docetaxel produced statistically significant and clinically meaningful improvements in pathological complete response rates vs placebo plus FLOT in patients with resectable gastric cancer or gastroesophageal junction cancer.

Germany , German , Krankenhaus-nordwest , Salah-eddin-al-batran , Institute-of-clinical-cancer-research , University-cancer-center , Clinical-cancer-research , Gastrointestinal-oncology , Krankenhaus-nordwest-university-cancer-center , Esmo-congress , News- , Conference

Immutep Announces Publication of Abstracts at ESMO Congress 2023

Media ReleaseNew updated data from TACTI-002, including more mature Overall Survival data, will be presented during the Mini Oral session on Satur...

Australia , Sydney , New-south-wales , United-states , Frankfurt , Brandenburg , Germany , Australian , Enric-carcereny , Chris-basta , Florian-vogl , Katarzyna-kozak

Hygrovest Ltd welcomes dosing of first patient by investment ValoTx in Phase I trial

Hygrovest Ltd (ASX:HGV, OTC:MMJJF) welcomes the dosing by its Finland-based investment Valo Therapeutics Oy (ValoTx) of the first patient in a Phase I trial...

Heidelberg , Baden-wüberg , Germany , Helsinki , Eteläuomen-läi , Finland , Paul-higham , Krankenhaus-nordwest , Vincenzo-cerullo , University-of-helsinki , Hygrovest-ltd , Safety-data-committee

Valo Therapeutics Announces First Patient Dosed with PeptiCRAd-1 - Innovative Immuno-oncology

Valo Therapeutics Oy (ValoTx), the developer of novel, adaptable immunotherapies for cancer, announces that the first patient has been treated in its Phase I trial of PeptiCRAd-1 (Peptide-coated Conditionally Replicating Adenovirus) in three tumor types. PeptiCRAd-1 is an innovative approach never before used ...

Germany , Heidelberg , Baden-wüberg , Frankfurt-am-main , Hessen , Helsinki , Eteläuomen-läi , Finland , Krankenhaus-nordwest , Paul-higham , National-center , Safety-data-committee

Immutep receives approval for efti trial with Merck's PD-L1 inhibitor

Immutep receives approval for efti trial with Merck's PD-L1 inhibitor
miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.

Germany , German , Marc-voigt , Krankenhaus-nordwest , Institute-of-clinical-cancer-research , German-federal-institute-for-vaccines , German-federal-institute , Clinical-cancer-research ,

Immutep : Receives Approval to Initiate INSIGHT-005 Trial Evaluating Eftilagimod Alpha and Anti-PD-L1 Therapy BAVENCIO®

Media Release



Investigator-initiated study jointly funded with Merck KGaA, Darmstadt, Germany, will evaluate dual immuno-oncology combination of... | May 1, 2023

Germany , United-states , Australia , Sydney , New-south-wales , Australian , German , Marc-voigt , Krankenhaus-nordwest , Nasdaq , Drug-administration , Merck-kga

Immutep Receives Approval to Initiate INSIGHT-005 Trial Evaluating Eftilagimod Alpha and Anti-PD-L1 Therapy BAVENCIO®

Immutep Receives Approval to Initiate INSIGHT-005 Trial Evaluating Eftilagimod Alpha and Anti-PD-L1 Therapy BAVENCIO®
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Germany , United-states , Australia , Sydney , New-south-wales , German , Australian , Marc-voigt , Krankenhaus-nordwest , Chris-basta , Corporate-communications , German-federal-institute-for-vaccines

Immutep in clinical trail collaboration with Merck KGaA and Pfizer

Research will focus on eftilagimod alpha and avelumab for the treatment of urothelial cancer - News - PharmaTimes

Germany , Krankenhaus-nordwest , Marc-voigt , Pfizer , Merck-kga , Merck-kgaa , Institute-of-clinical-cancer-research , Clinical-cancer-research , Immutep- , Rial- , Erck-kgaa ,